Recap: Horizon Therapeutics Q2 Earnings

Shares of Horizon Therapeutics HZNP were unchanged after the company reported Q2 results.

Quarterly Results

Earnings per share fell 18.37% over the past year to $0.40, which beat the estimate of $0.34.

Revenue of $462,779,000 up by 44.33% from the same period last year, which beat the estimate of $326,640,000.

Looking Ahead

The upcoming fiscal year's revenue expected to be between $1,850,000,000 and $1,900,000,000.

Details Of The Call

Date: Aug 05, 2020

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/o3j7ts3j

Price Action

52-week high: $63.72

Company's 52-week low was at $22.84

Price action over last quarter: Up 47.01%

Company Description

Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the inflammation segment. It markets medicines in the areas of orphan diseases, rheumatology and inflammation division. The majority of revenue is generated in the United States.